“Comparative Analysis of Efficacy, Cost Analysis and Prevalence of Urinary Tract Infection in Type II Diabetic Patients Exposed to Dapagliflozin, Dapagliflozin Propanediol Monohydrate, Dapagliflozin with Metformin Prospective Observational Study

Background: Type 2 diabetes mellitus(T2DM) is a chronic metabolic disorder carrying an enormous burden of morbidity and mortality because of its characteristic complications, many of which are preventable with strict glycemic control.Initial management of T2DM consists of non -pharmacological interventions; if those fail, an oral anti-diabetic drug, most typically metformin is started.Combination therapy is initiated only when monotherapy fails to achieve glycemic control.Currently, Dapagliflozin may be considered a second line agent to treat patients with T2DM and has the potential to provide a first line option particularly for patients with contraindications or lack of glycemic control on metformin, the conventional first line agent.Methods: A prospective observational study was conducted for 150 patients and their records from 2023-2024 were included in this study based on the inclusion and exclusion criteria.The case records were reviewed and evaluated on the basis of gender, age, efficacy results, prevalence of urinary tract infections and cost analysis results were collected.The collected data was entered and analyzed by using Microsoft Excel and the statistical calculation were also conducted by using ANOVA.Results: A total of 150 patients were included in our study.On comparing three group of subjects with different drugs Group A which was provided with Dapagliflozin Propanediol Monohydrate involved 20 male patients and 20 female patients, Group B which was provided with Dapagliflozin involved 18 male subjects and 22 female subject and Group C which was provided with Dapagliflozin with Metformin include 22 male subjects and 18 female subjects.The majority of reduction or most efficacious is Group C. Also, by comparing three group of drugs for its prevalence of UTI GROUP C indicates less prevalence rate as compared to Group A and Group B. Conclusion:In conclusion, this study effectively compares the efficacy and cost analysis of three diabetic drugs in managing type 2 diabetes, with a particular focus on their impact on the prevalence of UTI.Our findings suggests that Dapagliflozin with metformin has highest efficacy and also cost effectiveness compared to Dapagliflozin Propanediol Monohydrate and Dapagliflozin.Similarly, Dapagliflozin with metformin has lowest prevalence for UTI as compared to Dapagliflozin Propanediol Monohydrate and Dapagliflozin.These results provide critical insights for clinicians when selecting antidiabetic medications, emphasizing the importance for considering UTI risk alongside glycaemic control.Further research is recommended to explore long term outcomes and potential strategies for mitigating UTI risk in diabetic patients.